Compare ADMA Biologics Inc (ADMA) vs ServiceNow Inc (NOW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs ServiceNow Inc — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while ServiceNow Inc trades at $106.78 (market cap $114.20B). The key difference: ServiceNow Inc is far larger — about 53.6× ADMA Biologics Inc's market cap. Which is the better fit depends on your goals.
| ADMA | NOW | |
|---|---|---|
Market Cap | $2.13B | $114.20B |
Sector | Health | Technology |
52-Week High | $20.38 | $204.60 |
52-Week Low | $7.60 | $83.00 |
Enterprise Value | $2.20B | $111.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
ServiceNow (NOW) trades at $107.93, up 1.51% today, with a bullish technical outlook supported by positive moving averages. The company reported strong revenue growth to $13.28 billion in 2025 and has beaten earnings estimates in three of the last four quarters. Recent news highlights AI-driven growth potential and conference presentations, while analyst consensus remains strongly bullish with an 85.51% buy rating.
The outlook for NOW is positive due to robust fundamentals and AI adoption, but high valuation multiples (P/E 64.24) pose a risk if growth slows. Upside to the $136.43 price target offers potential, yet investors face volatility from competitive pressures and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →
